CYP19A1 and depressive symptom measurement: Whereas an impact of chemotherapy on psychological well-being has been reported previously in premenopausal women [27, 28], large placebo-controlled trials have not found evidence of associations between tamoxifen or aromatase inhibitors and depression or mental health [29, 30].